Does ivermectin treat COVID-19 or cancer?
Written by AI from saved sources. A script checks every quote word for word, and a second AI compares each claim with its source. How we work and corrections
Large trials in outpatients, or patients outside hospital, have not established a meaningful COVID-19 treatment benefit. The human evidence covered here includes a small study of combined drugs but does not establish that ivermectin treats cancer. It is a real human medicine, approved for certain parasitic worms and, in skin products, head lice and rosacea.
Checked against: FDA, ACTIV-6, PRINCIPLE, October 2026.
Why people believe it
Cochrane reviewers describe hopes for a low-cost pandemic treatment that would be widely available. They also describe early small studies suggesting large reductions in deaths. For cancer, a celebrity’s account of friends recovering after taking ivermectin and another drug received attention. It was a claim, not verified treatment evidence. These are understandable reasons to look more closely.
“Does it help you recover from COVID faster?”
ACTIV-6 randomly assigned treatment to outpatients with mild to moderate COVID-19. Patients and researchers did not know who received ivermectin or a placebo, a dummy treatment. Of 1,800 people assigned, 1,591 completed the trial. Sustained recovery meant at least three symptom-free days in a row. The median, or middle value, for time to sustained recovery was 12 days with ivermectin and 13 with placebo. The authors concluded that ivermectin did not significantly improve recovery time compared with placebo in these outpatients.
PRINCIPLE compared ivermectin plus usual care with usual care alone for time to first recovery reported by patients. It found a median reduction of about two days. But the chance of meeting the trial’s preset level for a meaningful benefit was low. Patients knew their treatment. The authors said expectations might have influenced the small differences in recovery reported by patients. At six months, 74% of ivermectin respondents versus 71% of usual-care respondents felt fully recovered.
“Does it keep people out of hospital or save lives?”
In ACTIV-6, hospitalisations or deaths by day 28 numbered ten with ivermectin and nine with placebo. PRINCIPLE found no evidence that ivermectin reduced hospital admissions. Cochrane’s 2022 review assessed outpatients with no symptoms or mild COVID-19. It judged that adding ivermectin to standard care probably had little or no effect on deaths from any cause by day 28, compared with standard care with or without placebo. For hospital patients with moderate to severe COVID-19, it remained very uncertain whether adding ivermectin to standard care prevented death or worsening illness, or increased serious adverse events, compared with standard care with or without placebo.
“But does it kill cancer cells?”
A 2021 study reported cancer-cell death in mice used to study triple-negative breast cancer. It found that ivermectin plus an anti-PD1 antibody limited tumour growth. However, neither treatment alone showed efficacy in that mouse model. In June 2026, the journal’s editor warned about similar images and unavailable original data, advising caution.
A 2025 conference summary reported that nine patients had enrolled in a trial of ivermectin plus another drug, balstilimab. They had triple-negative breast cancer that had spread. Among eight patients assessed, one had a partial response, one had stable disease and six had worsening disease. The 2025 summary reported that it was too early to assess overall survival. The authors favoured further investigation. But this small study of combined drugs cannot establish ivermectin’s separate effect or a survival benefit.
Thinking tool: how big, and how well tested?
Cochrane’s reviewers described early studies as mainly small. They also described limits in how the studies were designed, run and reported. Their 2022 update said better-quality trials with more participants increased confidence in the evidence. They also excluded seven earlier trials that did not meet their rules. Ask about participant numbers and fair comparisons together, rather than counting favourable papers.
Use this on other claims: ask whether the headline rests on a small early study or a well-run test in people.
Official positions, with dates
FDA, 5 April 2024: no approval or authorisation for preventing or treating COVID-19 in humans or animals. Available trials did not demonstrate effectiveness against COVID-19 in humans. EMA, 22 March 2021: use for COVID-19 prevention or treatment could not be recommended outside controlled clinical trials. WHO, 10 November 2023, retained in its August 2025 guideline: strongly against use for non-severe COVID-19. For severe or critical disease, use only within trials. UCLA Health, 12 May 2026: no trials in people had shown ivermectin safe or effective for cancer.
What people also ask
What does ivermectin treat in humans? FDA-approved uses include two parasitic-worm diseases: intestinal strongyloidiasis and onchocerciasis. Some skin products treat head lice and rosacea.
Are there two different types of ivermectin? Human and animal products have different formulas. FDA says animal products’ safety in humans is unknown.
Does ivermectin react with other drugs? FDA says even doses for approved human uses can interact with medicines such as blood thinners.
What does ivermectin do to the human brain? FDA lists seizures and coma among possible overdose effects. That describes overdose, not what every user experiences.
Check it yourself (5 minutes)
- Open Duke Scholars’ 2022 ACTIV-6 abstract.
- Find “Conclusions”.
- Does the conclusion support using ivermectin for mild to moderate COVID-19?
What you should have found
“These findings do not support the use of ivermectin in patients with mild to moderate COVID-19.”
Before you forward this: does the box at the top say exactly what the sources below say?